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INTRODUCTION
This chapter addresses the management of BP in adult CKD
patients (specifically non-dialysis-dependent CKD [CKD
ND]) with diabetes mellitus. Previous guidelines1,30 have
used the term ‘diabetic nephropathy’ or ‘diabetic kidney
disease.’ This Work Group decided to use the term ‘diabetes
with CKD’ in recognition of the fact that many patients who
have co-existing diabetes and CKD do not undergo kidney
biopsy and may have other forms of kidney damage with
or without the changes that characterize diabetes. Examples
of alternative pathologies include nephroangiosclerosis,
atheromatous embolism, atherosclerotic renal artery disease,
or glomerulonephritis. In addition, there is evidence that the
classic histological features of diabetic nephropathy can on
occasion be found in patients who do not have a high urine
albumin level.194–196 Also, progressive loss of excretory kidney
function has been observed in the absence of progression
from microalbuminuria to overt proteinuria in some patients
with diabetes.197
Observational studies in the general population provide
strong evidence of a linear relationship between BP and risk
of cardiovascular events.21 A large number of RCTs have also
shown that drugs that reduce BP also reduce the risk of
subsequent cardiovascular events.198 The benefits of BP
reduction observed in clinical trials involving high-risk
patients have also been shown to be consistent across a
range of baseline BP levels in recent, large meta-ana-
lyses.198,199 In addition, baseline BP levels have been shown
to be a powerful determinant of the subsequent risk of kidney
failure in large population-based studies from around the
world.148,200
Diabetes increases the risk of CVD by a factor of two to
three at every level of systolic BP,201 and this risk is further
potentiated by the presence of CKD. In addition, type 2
diabetes is a leading cause of CKD, accounting for 30 to 50%
of new cases of kidney failure in the industrialized world.202
Microalbuminuria is one of the earliest detectable manifesta-
tions of kidney disease in patients with diabetes, with a
prevalence of 25% after 10 years of diabetes and an annual
rate of progression to overt nephropathy of approximately
3%.203 The risk of incident and progressive microalbumin-
uria is highly associated with BP levels.204 Progression of
retinopathy is also closely associated with high BP.205–208 It is
therefore important that the clinician is provided with clear,
evidence-based recommendations on the use of BP-lowering
drugs in the management of patients with diabetes and CKD.
This management should also include interventions for
multiple risk factors, which have been shown to improve
outcomes in patients with diabetes.209–211
The Work Group recognizes that the benefits of BP
reduction in patients with diabetes and CKD may include
reductions of the risks of progressive loss of kidney function,
CVD and progression of diabetic retinopathy. We also took
into account the fact that the effects of BP reduction may
differ among outcomes; for instance, a lower achieved BP
may be associated with an increased risk of one outcome but
a reduced risk of another.
These recommendations are not stratified by CKD stage as
there are remarkably few studies in which the effect of BP-
lowering therapy has been reported according to CKD stage.
The Work Group could find no evidence that the balance of
benefits and harms of BP-lowering therapy, or specific types
of therapy, varied with the GFR—other than the known risks
of hyperkalemia, particularly with agents that directly
interfere with renin–angiotensin–aldosterone system (see
Chapter 2).
4.1: We recommend that adults with diabetes and CKD
ND with urine albumin excretion o30mg per 24
hours (or equivalent*) whose office BP is consistently
4140mmHg systolic or 490mmHg diastolic be
treated with BP-lowering drugs to maintain a BP that
is consistentlyr140mmHg systolic andr90mmHg
diastolic. (1B)
*Approximate equivalents for albumin excretion rate per 24 hours—
expressed as protein excretion rate per 24 hours, albumin/creatinine ratio,
protein/creatinine ratio, and protein reagent strip results—are given in
Table 1, Chapter 1.
RATIONALE
K RCTs that have examined various BP targets or compared
active treatment with placebo, along with observation
studies, have been consistent in suggesting that lowering
BP so that it is consistentlyo140/90mmHg will prevent
major cardiovascular events. Lowering BP to these levels
is also likely to reduce the risk of progressive CKD.
K The evidence for the benefit of further lowering of the BP
target is mixed, with modest cardiovascular benefits in
patients with diabetes partly offset by increases in the risk
of serious adverse effects in trials, and inconsistency in
results among observational studies using clinical trial
datasets.
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Recommendation 4.1 applies to diabetic patients with CKD,
defined as a GFRo60ml/min/1.73 m2, and normal albumin
excretion (normoalbuminuria) prior to the use of BP-
lowering drugs such as ACE-Is or ARBs. Several studies have
shown that this is not a rare occurrence in patients with type
2 diabetes.195,196,212–217 For example, in the National Health
and Nutrition Examination Survey (NHANES), 36% of
adults with type 2 diabetes and a GFR o60ml/min/1.73 m2
had normal urine albumin levels.195 A population-based
study in Japan found 262 of 3297 people (7.9%) with type 2
diabetes and a GFRo60ml/min/1.73 m2 had a normal AER.
The diabetic patients with CKD but a normal AER were older
and included a higher proportion of women and patients
with hypertension, hyperlipidemia, and CVD but fewer
smokers, compared with the diabetic patients with a normal
AER and preserved GFR.217
A long-term follow-up study of participants with type 1
diabetes in the Diabetes Control and Complications Trial and
the Epidemiology of Diabetes Interventions and Complica-
tions (DCCT/EDIC) study showed that 24% of those
who developed a GFR o60ml/min/1.73 m2 had an AER
o30mg per 24 hours at all previous evaluations,218
indicating that normoalbuminuric CKD is also an important
entity in type 1 diabetes.
RCTs. The Work Group could not identify any RCTs in
which patients with CKD and normoalbuminuric diabetes
had been randomized to various BP targets. Several trials have
been completed in broader populations with diabetes, some of
whom had CKD at study entry. These are summarized here.
In the United Kingdom Prospective Diabetes Study
(UKPDS) 38,219 patients with diabetes, a minority of whom
also had nephropathy, were randomized to BP o150/
85mmHg or o180/105mmHg. Tighter BP control was
associated with a reduction in risk of diabetes-related death,
stroke, and progression of retinopathy.
The HOTstudy220 recruited 18,790 adults with diastolic BP
between 100 and 115mmHg and randomized them to one of
three diastolic BP targets: r90, r85, and r80mmHg.
Among the 1501 subjects with diabetes (a relatively small
proportion, suggesting under-representation of diabetics), the
risk of major cardiovascular events in the group targeted to a
diastolic BP r80mmHg was half that of the group targeted
to 90mmHg. Baseline data on cardiovascular risk factors
were not provided for the diabetic subgroup, leading some
commentators to speculate whether this result was due to
imbalance between the groups rather than to a genuine
treatment effect. No data were given on urinary albumin
excretion in the diabetic subgroup.
The Appropriate Blood Pressure Control in Diabetes
(ABCD) study was a 5-year prospective RCT comparing
intensive and moderate BP control in patients with diabetes.221
The hypertensive arm comprised diabetic patients with a
diastolic BP 490mmHg randomized to a diastolic BP target
of 75mmHg or 80 to 89mmHg. Patients assigned to the lower
BP target were also randomized to receive either nisoldipine or
enalapril. This arm of the trial was terminated early because of
a significantly higher incidence of myocardial infarction (a pre-
specified secondary end point) in the nisoldipine group.222 At
5 years of follow-up, there was no difference in the rate of pre-
specified kidney outcomes or cardiovascular outcomes between
the group targeted to 75mmHg and the group targeted to 80
to 89mmHg but a significantly lower incidence of death in the
75mmHg group.183
The normotensive arm in the ABCD study comprised
diabetic patients (around 30% of whom had CKD, as defined
on the basis of albumin excretion) with a baseline BPo140/
90mmHg who were randomized to placebo or active
treatment (and in that group, further randomized to either
enalapril or nisoldipine) titrated to reduce the diastolic
BP to 10mmHg below baseline.223 As compared with less-
intensive treatment, intensive treatment (to the lower BP
target) was not associated with any difference in the change
in creatinine clearance over the study period but was
associated with lower risks of progression from normo-
albuminuria to microalbuminuria and from microalbumin-
uria to overt proteinuria, as well as a reduced risk of stroke
and of progression of retinopathy. The inclusion criteria for
the normotensive arm of ABCD prevents reliable extra-
polation of this finding to patients whose baseline BP is
4140/90mmHg.
The ACCORD study159 randomized 4733 patients with
diabetes and high cardiovascular risk to a systolic BP target
o140mmHg or o120mmHg. A total of 39% of patients
had an elevated urinary AER. There was no difference
between the two groups in the primary composite end
point (non-fatal myocardial infarction, non-fatal stroke, or
cardiovascular death). However, the lower systolic BP
target was associated with a significant reduction in the risk
of stroke (62 events with o140mmHg target vs. 36 events
with o120mmHg target, P¼ 0.01), a pre-specified second-
ary end point, but also with a significant increase in rate of
serious adverse events (30 events vs. 77 events, respectively;
Po0.001).224
As compared with the group targeted to o140mmHg,
the group targeted to o120mmHg had higher rates of
hyperkalemia and elevations in SCr level. The mean GFR was
significantly lower in the intensive-therapy (lower-target)
group than in the standard-therapy group at the last visit.
There were significantly more instances of a single GFR
measurement o30ml/min/1.73 m2 in the intensive-therapy
group than in the standard-therapy group (99 events vs. 52
events, respectively; Po0.001), but the proportion of
participants with more than one GFR reading o30ml/
min/1.73 m2 was similar in the two groups (38% vs. 32%,
respectively; P¼ 0.46). The frequency of macroalbuminuria
at the final visit was significantly lower with intensive therapy
than with standard therapy, and there was no between-group
difference in the frequency of kidney failure or initiation of
dialysis (in 58 patients vs. 59 patients, P¼ 0.93).159
The ACCORD trial also showed that intensive glycemic
control and combination lipid-lowering treatment, but not
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intensive BP control, was associated with a reduction in the
rate of progression of retinopathy.224
Observational studies. There have been several large
observational studies of patients with diabetes, CKD, or
both, most of which found a lower risk of cardiovascular or
kidney outcomes in people with lower BP.148,225 These studies
have been cited by many previous guidelines and used to
support a BP target of o130/80mmHg for patients with
CKD or diabetes. However, none of these studies prove
causality and it is equally possible that higher BP, whether
occurring before initiation of BP-lowering treatment or after,
is simply a marker for more severe disease, which in turn has
a poorer prognosis.22
Among patients screened for the Multiple Risk Factor
Intervention (MRFIT) trial, there was a strong, graded,
positive relationship between baseline BP and subsequent risk
of kidney failure; the association was weaker among older
men, blacks, and men with diabetes.148 In the diabetic
subgroup of MRFIT participants,201 the risk of cardiovascular
death increased to a greater degree with increasing risk factors,
including systolic BP, than in the non-diabetic subgroup.
A strong association between baseline BP and subsequent
risk of kidney failure was also demonstrated in an Okinawan
study.226 After adjustment for age and BMI, there was a
significant, positive association between systolic BP and the
risk of diabetic kidney failure, with a relationship also
demonstrated for diastolic BP in women only.
The Pittsburg Epidemiology of Diabetes Complications
(EDC) study227 reported on 589 patients with childhood-
onset diabetes. A graded association between baseline BP and
subsequent risk of major events was found.
Data from the Cardiovascular Health Study and the
Atherosclerosis Risk In Communities study158 showed that
among participants with CKD, there was a J-shaped
relationship between systolic BP and risk of stroke, with a
higher risk of stroke with a systolic BP o120mmHg; this
relationship was not seen in those without CKD.
Post hoc analyses of RCTs. Post hoc analyses of several large
RCTs have indicated various relationships between achieved
BP and outcomes.
A post hoc analysis of achieved BP and outcome in the
Irbesartan Diabetic Nephropathy Trial (IDNT)228 indicated
that systolic BP o120mmHg was associated with an
increased (rather than decreased) risk of cardiovascular events.
A post hoc analysis of UKPDS 36,229 irrespective of
treatment allocation, revealed a significant association
between higher systolic BP and higher risk of clinical
complications over a systolic BP range of 115 to 170mmHg.
The International Verapamil SR Trandolapril (INVEST)
study recruited patients with hypertension and CAD and
compared the effects of verapamil and atenolol. Trandolapril,
hydrochlorothiazide, or both were added to achieve either a BP
o140/90mmHg or a BP of o130/85mmHg in patients with
diabetes or kidney impairment.230 In an analysis of achieved BP
among participants with diabetes (irrespective of their rando-
mized treatment assignments), those who achieved tight BP
control (i.e., a systolic BP o130mmHg) had similar rates of
cardiovascular outcomes, and higher rates of death, than those
with usual BP control (i.e., systolic BP, 130 to 140mmHg).
Both groups had better outcomes than did a third group with
poor BP control (i.e., systolic BP4140mmHg). The increased
risk of mortality in the tight-control group persisted during an
extended follow-up period.231
The Action in Diabetes and Vascular Disease: Preterax and
Diamicron Modified Release Controlled Evaluation (AD-
VANCE) collaborative group showed that the addition of
perindopril plus indapamide to current therapy used in
patients with type 2 diabetes and high cardiovascular risk
reduced the rate of major or microvascular events.232 In a
secondary analysis, kidney events (mostly measures of
appearance or worsening of urinary AER) were less frequent
with a lower achieved BP at the follow-up visit.233 The
absolute risk reductions for cardiovascular and kidney end
points associated with active treatment (irrespective of BP)
were greater among patients with CKD 3–5 than among
patients with CKD 1–2.234
Interpretation. The Work Group believed that the data
for reducing usual systolic BP to r140mmHg and diastolic
BP to r90mmHg were strong, on the basis of the data
presented above, as well as the clear relationship between
BP levels and the risk of cardiovascular and kidney out-
comes consistently noted in observational studies in both the
general population21,198,199 and in patients with diabetes with a
systolic BP 4140mmHg and a diastolic BP
490mmHg.229,233 Further support is provided by reports
from a number of clinical trials or trial subgroups demonstrat-
ing that BP-lowering therapy prevents cardiovascular and
kidney events in patients with diabetes, most of whom had BP
levels 4140/90mmHg at trial entry.183,219,221,223,232 There are
few data for individuals with diabetes and CKD, but those that
are available have reported broadly consistent findings.234
The Work Group does not believe that the evidence is
sufficiently strong to support a lower target BP level for all
patients with diabetes and CKD. Some support for lower BP
targets is provided by the ACCORD and ABCD trials
population. However in ACCORD, these benefits must be
balanced against the increased risk of adverse events. As a
result, it was felt that the risk-to-benefit ratio is likely to be
unfavorable for at least some groups of individuals with
diabetes and CKD. These include patients with diabetes and
non-albuminuric CKD, who may be likely to have additional
co-morbidities; the elderly, who are prone to falls; patients
with marked systolic hypertension; and those with severe
autonomic neuropathy. Such patients may have been under-
represented in the RCTs and observational studies.
A target BP of r140 systolic and r90mmHg diastolic
may appear to require less aggressive therapy than the targets
recommended in some other guidelines for patients with
diabetes. However, whether this is true depends on how
targets are interpreted by clinicians. There is extensive
evidence from routine clinical practice that many patients
do not achieve the targets set in guidelines; instead, achieved
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values often have a normal distribution around the target.22
This distribution of values is the reason for the wording we
have chosen for the recommendation statements: that BP be
‘‘consistently’’ below a given level. For instance, to account
for random fluctuations in resting office BP over time, the
intervention threshold needs to be significantlyo130mmHg
to achieve a systolic BP consistently o130mmHg.
The Work Group, therefore, is confident that most
individuals with diabetes and CKD should have their usual
BP lowered to be consistently r140/90mmHg (hence the
grade of 1B for recommendation 4.1), and that targets lower
than r140/90mmHg could be considered on an individual
basis for patients believed to be more likely to benefit than to
be harmed by the treatment (e.g., patients not already on
several BP-lowering agents, younger individuals, or persons
at high risk of stroke).
Overall, the evidence supporting the statement that
systolic BP should be lowered to r140mmHg is at least
level B. However, the evidence supporting the implication
that systolic BP needs to be lowered further, for instance to
r130mmHg, is weaker. This grading should not, therefore,
be taken to imply that no further research is required on the
question of lower BP targets in this group.
Comparison with current guidelines. Recommendation 4.1
is consistent with recommendations made by numerous
international and national guidelines for the general popula-
tion,9,30,235–244 all of which agree on a treatment goal ofr140/
90mmHg on the grounds that BP-lowering drugs reduce the
risk of all-cause and cardiovascular mortality in people whose
BP is 4140/90mmHg. There is no reason to expect that
patients with diabetes and CKD are less likely to have a benefit.
Although there is observational evidence that the risk of CVD
is higher among diabetic patients than non-diabetic patients at
any given BP, these findings do not, in the absence of RCT
evidence, support a recommendation that BP should be
lowered further than is recommended in diabetic patients.
The Work Group is aware that this recommendation
appears more conservative than the recommendations of
some other international and national guidelines that
recommend a BP target r130/80mmHg for patients with
diabetes and CKD.1,9,30,237–240,243,245–247 However, there is
insufficient high-quality evidence from RCTs to support a
lower target for patients with diabetes and CKD (which we
defined as a GFR o60ml/min/1.73 m2) who do not have an
increased urinary AER. All other guidelines have relied on
observational evidence to support a lower systolic BP
threshold for patients with diabetes. The Work Group did
not consider the evidence from the HOT220 and ABCD221
trials strong enough to justify a recommendation to lower the
target diastolic BP to r80mmHg.
The Work Group analyzed the evidence base for the existing
guidelines carefully to ensure that the apparent departure from
accepted wisdom was justified. Few existing guidelines specify
how patients with normoalbuminuric CKD and diabetes
should be treated with BP-lowering drugs, with the majority
advising a BP target of r130/80mmHg for all patients with
diabetes, irrespective of GFR or albuminuria. Although the
grades (and grading system) of these recommendations vary,
all supporting statements acknowledge that the evidence is
largely observational. For instance, many guidelines refer back
to JNC 7,9 which qualified the recommendation with the
caveat, ‘although available data are somewhat sparse to justify
the low target level of 130/80mmHgy.’ The JNC 7 goes on
to cite the American Diabetes Association guidelines245 and the
supporting literature analysis,235 which rely on the HOT
findings220 for justification of the 80mmHg diastolic BP
target245 and on Systolic Hypertension in the Elderly Program
(SHEP)151 and Systolic Hypertension in Europe (Syst-Eur)
trial248 (both studies of the general population) for the
140mmHg systolic BP target. Finally, the JNC 7 states that
‘Epidemiological studies indicate that there is a benefit to
reducing systolic BP still further to 130mmHg or below’, citing
two references, UKPDS 36229 and a study from Allegheny
County that contains no data on BP.249
We have not made recommendations about the choice of
the BP-lowering drug to be used in patients with CKD and
diabetes who do not have elevated rates of urinary albumin
excretion. Although there is some evidence that inhibitors of
the renin–angiotensin system might prevent an increase in
urinary AER,250,251 particularly in the presence of higher
BP,252 and might also reduce cardiovascular risk, such studies
have not been performed in patients with reduced GFR but
normal urinary albumin excretion. In such patients, the
balance of risks and benefits of the use of ACE-Is or ARBs
may well differ from the balance of their use for primary
prevention of diabetic kidney disease.
Considerations. Most interpretations of the observational
evidence predict that achieved BPs below a target of r140/
90mmHg in patients with CKD and diabetes would be
associated with additional benefit in the prevention of
both progressive kidney disease and cardiovascular events.
However, no RCTs have demonstrated such a benefit.
It remains possible that clinical harm could be done, at least
in some subgroups, by attempting to reach lower BPs.
Achieving lower BPs would require multiple drug treatments
in the majority of patients with CKD and diabetes,
particularly those with high pulse pressures. This has
implications both for adherence and for the cost of
treatment, of which the latter is particularly important in
resource-poor settings.
4.2: We suggest that adults with diabetes and CKD ND
with urine albumin excretion 430mg per 24 hours
(or equivalent*) whose office BP is consistently
4130mmHg systolic or 480mmHg diastolic be
treated with BP-lowering drugs to maintain a BP
that is consistently r130mmHg systolic and
r80mmHg diastolic. (2D)
*Approximate equivalents for albumin excretion rate per 24 hours—
expressed as protein excretion rate per 24 hours, albumin/creatinine ratio,
protein/creatinine ratio, and protein reagent strip results—are given in
Table 1, Chapter 1.
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RATIONALE
K Observational studies show that the level of urine
albumin predicts the risk of adverse cardiovascular and
kidney outcomes.
K BP lowering reduces the rate of urinary albumin
excretion, which may in turn lead to a reduced risk of
both kidney and cardiovascular events, although this has
not been shown in RCTs.
RCTs. The Work Group found only one RCT, from the
Steno Diabetes Centre in Copenhagen (Intensified Multi-
factorial Intervention in Patients With Type 2 Diabetes and
Microalbuminuria [Steno-2 study]) in which diabetic
patients with high urine albumin were selected and
randomized to two BP targets.209,211,253 In the Steno-2 study,
160 adults with microalbuminuria and type 2 diabetes were
randomized to intensive multifactorial intervention or to
conventional therapy. The intensive-care arm received ACE-I
or ARB irrespective of BP and had a BP target that was
initially 140/85mmHg but was reduced to 130/80mmHg
during the study, as compared too160/95mmHg which was
subsequently reduced to o135/85mmHg in the conven-
tional arm. However, intensive intervention also included
dietary advice, exercise, lipid-lowering treatment, help with
smoking cessation, vitamin supplementation, aspirin, and
intensified glycemic control. This intensive therapy was
shown to be associated with a reduced risk of CVD,
nephropathy, retinopathy, and autonomic neuropathy. The
improvements seen in the intensive-therapy group were
mostly in BP and the lipid profile, with only minor
differences between the two groups in glycemic control and
no differences in smoking, exercise measures, or body
weight.209
Observational evidence. There is strong observational
evidence of an association between higher BP and an increased
risk of worsening kidney function.148,201,225,254,255 Diabetic
patients with microalbuminuria are at increased risk of both
CVD256 and progressive kidney disease as compared to
diabetic patients with normal albumin excretion.256–258
Reduction of the rate of urinary albumin excretion during
treatment is associated with a better kidney and cardiovascular
prognosis.210,250,259–261 However, these associations do not
prove causation, and it remains possible, albeit highly unlikely,
that patients in whom the rate of urine albumin excretion
declines, either spontaneously or in response to treatment,
have intrinsically less severe disease than those in whom
no remission occurs. RCTs examining the effects of targeting
certain levels of urine albumin on clinically relevant end
points are needed before it can be concluded that treatment to
reduce the rate of urinary albumin excretion will improve
prognosis.
The Work Group therefore felt that benefits of targeting
lower BP levels were likely to be greater for individuals with
micro- or macroalbuminuria, so a target BP of r130/
80mmHg is suggested; however, stronger evidence is
required in this population, hence the grade of 2D.
4.3: We suggest that an ARB or ACE-I be used in adults with
diabetes and CKD ND with urine albumin excretion of
30 to 300mg per 24 hours (or equivalent*). (2D)
*Approximate equivalents for albumin excretion rate per 24 hours—
expressed as protein excretion rate per 24 hours, albumin/creatinine ratio,
protein/creatinine ratio, and protein reagent strip results—are given in
Table 1, Chapter 1.
RATIONALE
K Patients with diabetes and microalbuminuria are at
increased risk of kidney failure and cardiovascular events.
K ACE-Is and ARBs reduce the level of urine albumin in
patients with diabetes and microalbuminuria at baseline,
but data regarding the effects on kidney failure or
cardiovascular outcomes are limited.
Microalbuminuria is much more common than frank
proteinuria or albuminuria in patients with diabetes, but it is
also associated with an increased risk of kidney and
cardiovascular events. Several trials have shown a benefit of
ACE-Is or ARBs over placebo in patients with microalbumi-
nuria, irrespective of pre-treatment BP (See Supplementary
Tables 37–42 online).180,181,262–267 All of these trials studied the
effects of treatment on surrogate outcomes, most commonly
the transition to overt proteinuria; none demonstrate conclu-
sively that these improvements are associated with a reduction
in hard end points in this population, although this may be the
result of low event rates, inadequate statistical power, and short
follow-up times. The Work Group believes that ACE-Is and
ARBs should be the preferred classes of BP-lowering agent used
in patients with diabetes and microalbuminuria, although the
relatively weak available evidence is reflected in the poor grade
assigned to this guideline statement (2D).
We have not made statements about prevention of
microalbuminuria as this topic will be addressed in the
forthcoming KDOQI Diabetes guideline update.268
4.4: We recommend that an ARB or ACE-I be used in
adults with diabetes and CKD ND with urine albumin
excretion4300mg per 24 hours (or equivalent*). (1B)
*Approximate equivalents for albumin excretion rate per 24 hours—
expressed as protein excretion rate per 24 hours, albumin/creatinine ratio,
protein/creatinine ratio, and protein reagent strip results—are given in
Table 1, Chapter 1.
RATIONALE
K Patients with diabetes and high levels of urine albumin
are at a particularly high risk of adverse cardiovascular
and kidney outcomes.
K There is strong evidence from RCTs conducted in patients
with diabetes and CKD demonstrating that ACE-Is and
ARBs protect against kidney failure and increases in
albumin levels.
Individuals with elevated levels of urinary albumin or protein
and diabetes have some of the highest rates of cardiovascular
events and kidney failure of any group with CKD. For
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example, in IDNT and the Reduction of Endpoints in
NIDDM with the Angiotensin II Antagonist Losartan
(RENAAL) trial, the annual risk of the kidney and cardio-
vascular end points all approached 10%.182,184,259–261
RCTs. Several RCTs have provided high-quality evidence,
both in type 1 diabetes269 and type 2 diabetes,182,184 that
ARBs and ACE-Is reduce the risk of kidney outcomes270 as
compared to placebo or a dihydropyridine calcium-channel
blocker,184 although no clear effect on cardiovascular out-
comes has been established (possibly due to inadequate
power) (see Supplementary Tables 37–42 online). How-
ever, applicability of study findings to the entire CKD and
diabetes population is somewhat limited, because major
studies have excluded patients with clinically significant
CVD. There is high-quality evidence from trials of high-risk
individuals from the general population showing that ARBs
and ACE-Is improve cardiovascular outcomes,185,271–276
including in patients with diabetes.277,278 But these studies
did not focus on patients with clinically significant
albuminuria. In contrast, there was no benefit of ACE-Is as
compared to diuretic therapy in the CKD and diabetic
subgroups in ALLHAT,279 although, again, few of the study
patients were likely to have had frank albuminuria. Moreover,
ALLHAT showed clear BP differences in favor of diuretic
therapy over ACE-Is, making the comparison between the
two groups somewhat difficult. As the RCT data in this
population is strong and consistent, the level of evidence is
high (see Supplementary Table 37 online). The decision on
the grade of this recommendation statement (1B) was made
by a majority vote. The minority of Work Group members
supported an evidence grade of A.
The choice between an ACE-I and an ARB in CKD
patients is controversial. In general, the evidence for kidney
outcomes that supports the use of ACE-Is is older and applies
largely to type 1 diabetes, whereas the evidence supporting
the use of ARB comes from more recent trials in type 2
diabetes. For cardiovascular protection in patients with
diabetes, the evidence largely points to ACE-Is. The available
data are consistent, suggesting the effects of both classes of
agents are likely to be similar. Cost and availability may be an
important consideration in some countries. However, extra-
polations within and between drug classes must be made
with care: within-class effects on hard outcomes may differ
substantially and may depend on the dose, making
extrapolation to other drug classes problematic. A 2004
meta-analysis concluded that there was insufficient evidence
on the relative effects of ACE-Is versus ARBs on survival.280
We were unable to find trials directly comparing ACE-Is and
ARBs in patients with diabetes and albuminuria. No clear
difference between the effects of the two classes of drugs was
found in the large Ongoing Telmisartan Alone and in
Combination with Ramipril Global Endpoint (ONTARGET)
trial involving people at high cardiovascular risk, including
subgroups with diabetes or CKD.281,282 However, this study
was not powered to make this comparison, so a real
difference remains possible.
The data are even more scarce regarding the effects of other
drug classes on outcomes in patients with diabetes and
proteinuria. In IDNT, patients with proteinuria were rando-
mized to irbesartan, amlodipine, or placebo. Amlodipine did
not significantly affect the risk of kidney or cardiovascular
events as compared to placebo and was clearly inferior to
irbesartan for the prevention of kidney outcomes.184 Aldoster-
one antagonists can reduce the risk of proteinuria in non-
diabetic CKD patients109,283 and in patients with diabetic
nephropathy,108 but adequately powered studies are lacking.
In the opinion of the Work Group, ACE-Is and ARBs
are likely to be similarly effective in improving outcomes
in patients with diabetes and proteinuria. Practitioners
should therefore base prescribing decisions on the evidence
available for each class, the risk of side effects, and cost
considerations.
RESEARCH RECOMMENDATIONS
K Prospective RCTs of a risk-based approach to the
reduction of cardiovascular risk and kidney end points
are encouraged.
K Studies comparing various BP intervention thresholds
and targets among patients with diabetes, with or
without an increased urinary AER, and with or without
a reduced GFR are needed.
K Studies in which drug dose is titrated on the basis of the
urine albumin level (or change in GFR) are needed.
K Studies on the effects of non-dihydropyridine calcium-
channel blockers on long-term outcomes are needed.
K Prospective studies of add-on therapy (consisting of
thiazides, aldosterone antagonists, or DRIs) and reduc-
tion of sodium chloride intake on the effects of ACE-Is or
ARBs in patients with diabetes and CKD are encouraged.
K Prospective studies of the combination of ACE-Is and
ARBs in patients with diabetes and CKD are encouraged.
K Prospective studies of different target BP levels stratified
by GFR are encouraged.
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